NASDAQ:MCRB

Seres Therapeutics Earnings Date, Estimates & History

$7.10
+0.11 (+1.57 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.83
$7.34
50-Day Range
$6.99
$24.36
52-Week Range
$3.67
$38.50
Volume2.52 million shs
Average Volume2.35 million shs
Market Capitalization$650.93 million
P/E RatioN/A
Dividend YieldN/A
Beta3.93

Seres Therapeutics (NASDAQ:MCRB) Earnings Information

Seres Therapeutics last posted its quarterly earnings results on May 4th, 2021. The biotechnology company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.06. The firm had revenue of $5.72 million for the quarter, compared to analyst estimates of $5.30 million. Seres Therapeutics has generated ($1.12) earnings per share over the last year (($1.21) diluted earnings per share). Earnings for Seres Therapeutics are expected to grow in the coming year, from ($1.52) to ($0.98) per share. Seres Therapeutics has confirmed that its next quarterly earnings report will be published on Tuesday, August 3rd, 2021. Seres Therapeutics will be holding an earnings conference call on Tuesday, August 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Seres Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Seres Therapeutics (NASDAQ:MCRB) Earnings Estimates

2021 EPS Consensus Estimate: ($1.62)
2022 EPS Consensus Estimate: ($2.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20213($0.38)($0.29)($0.32)
Q2 20213($0.44)($0.39)($0.41)
Q3 20213($0.47)($0.39)($0.43)
Q4 20213($0.53)($0.39)($0.46)
Q1 20222($0.52)($0.47)($0.50)
Q2 20222($0.56)($0.48)($0.52)
Q3 20222($0.57)($0.49)($0.53)
Q4 20222($0.54)($0.36)($0.45)

Seres Therapeutics (NASDAQ MCRB) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
8/3/2021
(Confirmed)
 ($0.41)       
5/4/20213/31/2021($0.33)($0.39)($0.06)($0.39)$5.30 million$5.72 million  
3/1/202112/31/2020($0.28)($0.23)+$0.05($0.18)$8.78 million$17.56 million  
11/9/20209/30/2020($0.24)($0.36)($0.12)($0.36)$9.15 million$1.42 million  
7/28/2020Q2 2020($0.26)($0.28)($0.02)($0.28)$9.67 million$6.05 million
5/7/20203/31/2020($0.28)($0.28)($0.28)$8.01 million$8.19 million  
3/2/202012/31/2019($0.28)($0.25)+$0.03($0.25)$6.82 million$7.62 million  
11/5/2019Q3($0.26)($0.23)+$0.03($0.23)$6.69 million$7.03 million  
8/6/2019Q2($0.41)($0.24)+$0.17($0.24)$10.29 million$12.53 million
5/2/20193/31/2019($0.43)($0.55)($0.12)($0.51)$8.61 million$7.32 million  
3/6/201912/31/2018($0.67)($0.52)+$0.15($0.52)$3.78 million$10.63 million  
11/8/2018Q3($0.57)($0.54)+$0.03($0.54)$23.43 million$9.06 million
8/2/2018Q2 2018($0.69)($0.68)+$0.01($0.68)$5.22 million$4.61 million
5/9/2018Q1 2018($0.75)($0.69)+$0.06($0.69)$3.00 million$3.97 million
3/8/2018Q4 2017($0.73)($0.71)+$0.02($0.71)$3.00 million$3.06 million  
11/8/2017Q3 2017($0.39)($0.17)+$0.22($0.17)$17.29 million$23.00 million
8/3/2017Q2 2017($0.59)($0.69)($0.10)($0.69)$3.00 million$3.00 million  
5/4/2017Q1 2017($0.65)($0.63)+$0.02($0.63)$3.00 million$3.02 million  
3/16/2017Q4 2016($0.70)($0.6260)+$0.0740($0.63)$3.00 million$3.00 million
11/10/2016Q316($0.55)($0.46)+$0.09($0.46)$10.38 million$13.02 million  
8/11/2016Q216($0.46)($0.70)($0.24)($0.70)$4.20 million$3.00 million  
5/16/2016Q116($0.48)($0.50)($0.02)($0.50)$1.25 million$2.71 million  
2/25/2016Q4 2015($0.40)($0.41)($0.01)($0.41)
11/10/2015Q315($0.32)($0.38)($0.06)($0.38)  
8/6/2015Q215($0.30)($1.45)($1.15)
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.